multicenter, USA - 19 Mar `18Aclaris Therapeutics: Topical Solution

Official title: An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo

In brief: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.

Ages eligible: 18 Years to 65 Years

Locations: Aclaris Investigator Site 

  • Encinitas, California, United States, 92024
  • Los Angeles, California, United States, 90036
  • Worcester, Massachusetts, United States, 01655
  • Dallas, Texas, United States, 75390
  • Lynchburg, Virginia, United States, 24501

Status: Unknown, not recruiting

Start date: March 19, 2018
Completion date: September 30, 2019

Identifier: ClinicalTrials.gov NCT03468855

Contacts: To learn more about this study, you or your doctor may contact Aclaris Therapeuitcs. Please refer to this study by its NCT number.

FAQOther Questions

  • What tests should be done?

    A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...

  • Is there a traditional medicine to treat vitiligo?

    Traditional medicines may be helpful in chronic, metabolic, and stress-related conditions early in the disease manifestation, before extensive tissue and organ damage has occurr...

  • Which diseases most commonly accompany vitiligo?

    Vitiligo is an autoimmune disease and is frequently associated with other autoimmune diseases, acccording to a 10-year study. The exact diseases that accompany vitiligo can vary...